RaySearch and Radiology Oncology Systems partner to expand global cancer care with refurbished linear accelerators and RayStation software

In a move aimed at increasing access to radiation therapy globally, Sweden-based medical technology company RaySearch Laboratories AB (NASDAQ Stockholm: RAY-B) has announced a strategic partnership with California-based Radiology Oncology Systems, Inc. (ROS). The agreement is focused on integrating refurbished linear accelerators (linacs) with advanced treatment planning and oncology information systems, a dual-pronged approach that industry observers say could help close critical gaps in global cancer care infrastructure.

Why are RaySearch and Radiology Oncology Systems collaborating on refurbished linear accelerators?

The newly announced partnership seeks to address a longstanding but often overlooked problem in global oncology: the premature scrapping of linacs despite remaining functional utility. Today, radiation therapy centers in high-income markets routinely retire linacs after a decade of use—driven by depreciation cycles, OEM service cutoffs, or insurance regulations—even though the machines are technically capable of continued service for years.

By pairing these underutilized assets with RaySearch’s advanced software suites—RayStation, its flagship treatment planning system, and RayCare, its oncology information platform—ROS and RaySearch aim to offer turnkey radiotherapy solutions for under-resourced regions. These integrated offerings promise not only cost efficiency but also adherence to modern treatment protocols, extending the operational lifecycle of linacs while preserving clinical quality.

What is the significance of this move for global cancer treatment access?

The ROS-RaySearch initiative comes at a time when the World Health Organization (WHO) estimates that more than 70% of cancer deaths occur in low- and middle-income countries, where access to radiotherapy remains limited or nonexistent. Refurbished linac programs have historically struggled due to fragmented support, lack of integrated software, and maintenance uncertainty.

This partnership addresses these friction points. By bundling refurbished hardware with state-of-the-art software, the offering goes beyond basic access—it brings clinical sophistication to new geographies. According to early details, orders have already been secured across four oncology centers: two in Argentina using Varian Trilogy systems, one in the United States equipped with TrueBeam, and a center in Mexico employing the Elekta Versa HD—all integrated with RayStation.

How does this reflect on RaySearch’s broader strategy?

For RaySearch Laboratories, this partnership signals an active shift toward market expansion via sustainable and socially conscious modalities. Historically focused on software innovations for high-end academic and research centers, RaySearch now appears to be embracing a circular economy model. By enabling reuse of capital-intensive equipment, the company not only strengthens its ESG (environmental, social, and governance) credentials but also taps into a new revenue stream in emerging markets.

Chief Executive Officer and founder Johan Löf emphasized the alignment between the company’s mission and the partnership’s goals, stating: “Access to care is critical for us to fulfill our vision of a world where cancer is conquered. This partnership, with its combination of refurbished linacs and advanced software solutions, can really make a difference.”

What’s the strategic value for Radiology Oncology Systems?

For Radiology Oncology Systems, a company specializing in refurbished radiation therapy and diagnostic imaging equipment, the tie-up marks a strategic evolution from hardware-centric sales to value-added solution delivery. The company’s President, John V. Vano, underlined the importance of the collaboration in bridging care gaps: “Too many cancer patients around the world face a critical gap between their need for care and the advanced technology available. Our collaboration with RaySearch allows us to help our customers expand their access to critical, life-changing care.”

What’s the expert view on this circular approach to oncology tech?

Industry analysts and oncology professionals have long called for creative approaches to alleviate the global shortfall in radiotherapy services. According to Lancet Oncology Commission estimates, by 2035, 12 million patients worldwide will require radiotherapy annually, but half will lack access due to infrastructure and affordability issues.

The RaySearch-ROS partnership is viewed as an early response to that growing need. By enabling software-hardware interoperability across multiple OEMs (Varian, Elekta), and by facilitating clinical readiness with end-to-end digital support, the alliance stands apart from traditional equipment resale models. Analysts suggest this positions RaySearch well for deeper penetration in Latin America, Southeast Asia, and parts of Africa—regions where capital constraints often prevent the adoption of newer linac systems.

Is there early evidence of market traction?

Yes. The announcement highlighted initial deployments in four clinical centers—two in Argentina, one in the United States, and one in Mexico. While no financial figures were disclosed, the operational diversity of these centers—using systems from Varian Medical Systems, Elekta AB, and RaySearch’s own software stack—demonstrates technical agility and product maturity.

Such successful integrations could serve as case studies to onboard additional sites, particularly those in national cancer control programs or NGO-run clinics that prioritize cost-effective scalability.

What could come next from the partnership?

With initial orders secured and successful software-hardware pairings proven, industry insiders expect the next phase of the partnership to involve a formalized service and training ecosystem. This could include remote commissioning, cloud-based planning tools, and AI-assisted workflows using RaySearch’s software IP. There’s also speculation that ROS and RaySearch could jointly approach international donors and multilateral health organizations to fund scaled deployment programs.

While neither company has confirmed such plans, the move would be consistent with both partners’ expressed commitments to “expand access to care” and “advance sustainability in oncology delivery.”

How are investors reacting to the RaySearch-ROS partnership?

Investor sentiment around RaySearch Laboratories AB (NASDAQ Stockholm: RAY-B) remains cautiously optimistic, especially as the company diversifies its revenue base away from mature markets. While no stock movement data was linked to this specific announcement as of July 18, buy-side analysts covering European med-tech firms are likely to view the development as an alignment with global health priorities and circular economy trends.

With oncology device vendors under pressure to demonstrate both sustainability and global health value, the partnership could emerge as a differentiator in ESG portfolio inclusion decisions, particularly for institutional investors with emerging-market mandates.

Will the RaySearch partnership model scale globally?

Analysts expect further institutional partnerships to follow, particularly in regions with aging linac fleets and emerging government oncology budgets. If ROS and RaySearch can establish a sustainable service model and retain software subscription flows, the partnership could become a template for future circular economy-based oncology expansion.